The 7-Steps person-centred medication review process can be used at both initiation of new medications and when reviewing existing treatments, including non-pharmacological approaches. This process ensures a shared decision-making approach to prescribing, with discussion of risks and benefits of treatments and enable safe, sustainable and effective person-centred care.
The following 7-Steps are intended as a guide to structure the review process.
Step 1: Aim: What matters to the person?
Step 2: Need: Identify essential drug therapy
Step 3: Need: Does the person take unnecessary drug therapy
Step 4: Effectiveness: Are therapeutic objectives being achieved?
Step 5: Safety: Is the person at risk of ADRs or suffers actual ADRs?
Step 6: Sustainability: Is therapy cost-effective and environmentally sustainable?
Step 7: Patient-centred: Is the person willing and able to take therapy as intended?
The 7-Steps to appropriate polypharmacy demonstrate that the review process is not in fact a linear single event, but cyclical, requiring regular repeat and review (see figure below). The circle is centred on what matters to the individual, ensuring they are provided with the right information, tools and resources to make informed decisions about their medicines and treatment options. It should be used at both initiation and review of medicines.
See case studies for examples of applying the 7-step medication review process.
The following 7-Steps are intended as a guide to structure the review process. They are also available as a pdf by clicking on the image below.
Process
Review diagnoses and consider:
- Therapeutic objectives of drug therapy
- Management of existing health problems
- Prevention of future health issues, including lifestyle advice
Ask individual to complete PROMs (questions to prepare for my review) before their review
Person specific issues to address
- Ensure a person-centred approach
- Consider non-pharmacological options where appropriate
- Consider if vulnerable or at risk of dependency
Process
Identify essential drugs (not to be stopped without specialist advice*)
- Drugs that have essential replacement functions
- Drugs to prevent rapid symptomatic decline
* with advice from healthcare professional with specialist interest
Person specific issues to address
- Benzodiazepines and z-drugs used for anxiety or insomnia are not regarded as essential. They are only indicated for a maximum of two to four weeks
- If prescribed for long-term use consider potential of withdrawal reaction and provide support for reduction and stopping
Process
Identify and review the continued need for drugs
- what is medication for?
- with temporary indications
- with higher than usual maintenance doses
- with limited benefit/evidence for use
- with limited benefit in the person under review (see Drug efficacy & applicability (NNT) table)
Person specific issues to address
- Not indicated for long-term use
- Consider the potential for harm (low numbers for NNH)
Process
Identify the need for adding/intensifying drug therapy to achieve therapeutic objectives
- to achieve symptom control
- to achieve biochemical/clinical targets
- to prevent disease progression/exacerbation
- is there a more appropriate medication to achieve goals?
Person specific issues to address
- Can treatment be supported with non-pharmacological or psychological therapies where appropriate (such as sleep hygiene, CBT/cCBT resources)?
- Are alternative medicines more suitable for longer term management?
Process
Identify individual safety risks by checking for
Identify adverse drug effects by checking for
- specific symptoms/laboratory markers
- cumulative adverse drug effects (see ADR table)
- drugs used to treat side effects caused by other drugs
Medication Sick Day guidance
Person specific issues to address
- Consider risk of ADRs such as drowsiness, falls, memory impairment
- If treatment has been taken for long periods of time gradually taper to avoid withdrawal reactions. Abrupt cessation may produce confusion, toxic psychosis, convulsions or a condition resembling delirium tremors
- Consider if vulnerable or at risk of dependency
Process
Identify unnecessarily costly drug therapy by
- considering more cost-effective alternatives, safety, convenience
Consider the environmental impact of
- Inhaler use
- Single use plastics
- Medicines waste
- Water pollution
Person specific issues to address
- Check that all medicines are formulary choices
- Advise to only order what is needed, do not stockpile medicines
- Advise not to dispose of in household rubbish or in water waste. Promote safe disposal of medicines via community pharmacy
Process
Does the person understand the outcomes of the review?
Ensure drug therapy changes are tailored to individual’s preferences. Consider
- is the medication in a form they can take?
- is the dosing schedule convenient?
- what assistance is needed?
- are they able to take medicines as intended?
Agree and communicate plan
- discuss and agree with the individual/carer/welfare proxy therapeutic objectives and treatment priorities
- include lifestyle and holistic management goals
- inform relevant health and social care providers of changes in treatments across the transitions of care
Ask individual to complete the post-review PROMs questions after their review
Agreed plan
- Consider alternatives to prescribing where appropriate
- If the benzodiazepine or z-drug is to be stopped/ reduced then consider and agree reduction schedule with individual and set achievable goals
- Ensure awareness of potential for dependence or withdrawal effects, when to seek help and what actions to take
- Utilise available self help resources (e.g. NHS inform)
- Consider the use of PROMs and individualised dosing/reduction schedules
- Ensure use of shared decision-making tools during person-centred reviews
- Awareness of potential for dependency or withdrawal effects with B-Z medicines
- Consider non-pharmacological approaches where appropriate (e.g. sleep hygiene, CBT)